The global demand for complex regional pain syndrome (CRPS) market is estimated to be worth around US$ 103.7 million in the current year 2023. During the projection period from 2023 to 2033, the market is forecasted to expand at a CAGR of 2.2%. The analysis report by FMI further predicts the market to expand positively during the forecast years rising to US$ 129.2 million by 2033.
The increase in the number of individuals suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the significant reasons driving market development. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect the entire body or only the legs, arms, feet, and hands.
There are two forms of CRPS, each with identical symptoms and treatments. Complex regional pain syndrome (CRPS) Type I arises after an injury without any nerve damage (also known as reflex sympathetic dystrophy). Type II CRPS develops as a result of particular nerve damage or trauma.
The prognosis of complicated regional pain syndrome varies by individual. In most situations, CRPS is minor, and the patient progressively heals over time; but, in other cases, the symptoms are severe, resulting in long-term impairment. Also, CRPS affects both men and women equally, however, women are more likely to be impacted.
The exact etiology of complex regional pain syndrome (CRPS) is unknown. CRPS is caused by an injury or trauma in around 90% of patients. Leg immobility, soft tissue damage, fracture, sprain, or needle stick injuries produced during surgical procedures are all typical causes of injury. Further, in individuals with CRPS, peripheral nerve abnormalities include unmyelinated and weakly myelinated nerve fibers at the axon area, which creates aberrant neurological symptoms.
CRPS tissue has an increased level of inflammatory molecules such as cytokines and it is frequent in people with inflammatory and autoimmune disorders. Currently, the genetic propensity to complex regional pain syndrome is not being studied extensively.
A study on the family incidence of CRPS in Dutch patients discovered that CRPS may occur in a familial form, but the inheritance pattern remained unknown. The number of symptoms and the individual's medical history influence the diagnosis of CRPS. There are just a few diagnostic procedures for CRPS.
According to the incidence statistics, females are three times more impacted than males. Additionally, according to research done in the United Kingdom, one in every 3,800 persons gets CRPS each year. Therapy (Rehabilitation Therapy, Psychotherapy) or pharmaceuticals such as non-steroidal anti-inflammatory drugs, corticosteroids, and others can be used to treat CRPS.
| Attributes or Data Points | Details |
|---|---|
| Global Complex Regional Pain Syndrome (CRPS) Market Valuation in 2022 | US$ 101.9 million |
| Estimated Global Market Share in 2023 | US$ 103.7 million |
| Forecasted Global Market Size by 2033 | US$ 129.2 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 2.2% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 1.4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for complex regional pain syndrome (CRPS), in terms of value, was nearly US$ 95.1 million in the year 2018, according to FMI. During the years from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.4%. By the end of the year 2022, the overall valuation of the market reached about US$ 101.9 million.
CRPS is more frequent in women and can occur at any age, according to the National Institute of Neurological Disorders and Stroke (NINDS). Furthermore, 90% of instances were caused by trauma or injury. As a result, several people suffering from chronic pain drive the market growth.
Growth in research and development spending by both private and governmental entities, as well as favorable government legislation, are some of the key drivers projected to drive the market in the next years. Moreover, the Worldwide Research Foundation for RDS/CRPS, for example, developed an international research network to help educate medical professionals and promote research.
A Growing Number of People Suffering from Chronic Pain to Boost Demand
There are currently no medications authorized by the USA FDA for the treatment of complex regional pain syndrome. Physicians, on the other hand, recommended therapy and medications to treat chronic pain.
The USA Food and Drug Administration recently identified Neridronic acid as a breakthrough drug in clinical studies for complex regional pain syndrome. Also, the FDA has granted the medicine Fast-track and orphan drug designations. Intense research and development, an increase in the number of CRPS cases, and the successful completion of clinical studies are expected to accelerate the expansion of the complex regional pain syndrome market.
The growing number of non-profit initiatives, increased research and development funding by private and public organizations, and various government initiatives to raise awareness about the syndrome are expected to drive market growth during the forecast period. For example,
Rising research and development efforts and FDA approvals of new medications are likely to boost market expansion throughout the forecast period. For example,
Principal Consultant
Tight Regulatory Approval and High Medicine Costs to Hinder Market Growth
In the forthcoming years, tight regulatory approval and high medicine costs may limit the growth of the complex regional pain syndrome market. In addition to this, a dearth of in-depth knowledge of CRPS, a shortage of medical and behavioral pain management professionals, and a dearth of effective treatment choices are the primary challenges impeding the growth of the complex regional pain syndrome market. Furthermore, in poor nations, a dearth of information on the target ailment may limit market growth further.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 58.5% |
| Europe | 14.5% |
Patients' Increased Awareness of Disease Remittance Therapy Creating Opportunities for Complex Regional Pain Syndrome (CRPS) Manufacturers
North America is at the vanguard of regional growth and a significant revenue provider on a worldwide scale. Patients' increased awareness of disease remittance therapy, the expanding frequency of CRPS, and high public and private healthcare spending are all driving the region's rise.
Simple access to high-quality healthcare, good reimbursement regulations, a robust clinical pipeline, and the approval of innovative medications are the important reasons expected to drive revenue growth in North America. Additionally, the increased knowledge of disease remittance therapy among patients, the rising prevalence of CRPS, and high public and private healthcare spending are driving market expansion in these areas.
Simple access to high-quality healthcare, a robust clinical pipeline, and the approval of innovative medications are projected to boost market expansion in North America. Thus, due to the aforementioned reasons, North America possessed a 58.5% market share in 2022, registering a CAGR of 2.1% for the complex regional pain syndrome (CRPS) market in the assessment period between 2023 and 2033.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 48.7% |
| Germany | 4.1% |
| Japan | 3.2% |
Increasing Number of Patients Fueling Significant Adoption
Asia Pacific is expected to be a significantly growing market throughout the projection period. As many people live in cities, several patients in the region are growing. This, combined with rising healthcare spending, is likely to push Asia Pacific’s market. Over the projected period, favorable regulatory rules for medication approval are expected to enhance demand for the regional market.
The key tactics followed by prominent companies in the worldwide complex regional pain syndrome (CRPS) market have been an expansion in emerging countries and a high emphasis on early diagnosis, screening, monitoring, and pharmacological clinical development. Thus, Asia Pacific procured a 35% market share in the year 2022.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 1.4% |
| China | 2.5% |
| India | 2% |
| Australia | 1.8% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Drug-based Therapy to Remain Highly Sought after
Based on therapy type, drug-based therapy accounted for a great proportion of the complex regional pain syndrome (CRPS) market in 2020. This is mostly due to an increase in the prevalence of several forms of chronic pain, such as lower back pain, severe headache or migraine pain, and face discomfort.
The market for pain reliever medications is predicted to expand throughout the forecast period due to the world's expanding elderly population, sedentary lifestyle, and rising number of surgical operations. Thus, based on therapy type, drugs are anticipated to expand at a 2% CAGR in the complex regional pain syndrome (CRPS) market in the sales indicator period from 2023 to 2033.
| Category | By Therapy |
|---|---|
| Top Segment | Therapy by Drugs |
| Market Share in Percentage | 38.2% |
| Category | By Distribution Channel |
|---|---|
| Top Segment | Hospital Pharmacies |
| Market Share in Percentage | 48.2% |
The Hospital Pharmacy Category is Witnessing Huge Demand in the Complex Regional Pain Syndrome (CRPS) Systems Market
Based on end use, the hospital pharmacy category is predicted to expand at a notable rate in the market during the forecast period. Hospitals are the leading end, consumers of chronic pain treatment products, accounting for a significant market share of the market in 2020.
Pain management strategies are becoming increasingly common in hospitals, particularly for post-surgical pain. As a result of the increasing number of surgical operations worldwide, hospital pharmacy is likely to continue to generate strong demand for complex regional pain syndrome (CRPS).
The most common complex regional pain syndrome (CRPS) techniques are conducted in hospitals, notably for post-surgical pain, where the cost of monitoring and treating side effects creates a strong demand for complex regional pain syndrome (CRPS) medications and technologies. Thus, by distribution channel, the hospital pharmacy category is expected to hold the prominent market share for the complex regional pain syndrome (CRPS) market in the forecast period from 2023 to 2033.
Key Startup Players Operating in the Complex Regional Pain Syndrome (CRPS) Market
Before reaching the brain, the spinal cord stimulation system gathers and suppresses pain impulses. This method consists of a tiny device that, like a pacemaker, sends electrical pulses to the spinal cord. Also, this assists patients in better managing chronic pain and reducing their reliance on opioid drugs.
Nalu Medical is a firm located in the United States of America that is working on an implanted medical device. Also, it is used as an additional treatment for people suffering from persistent pain in the trunk or limbs. The company also provides an External Trial Stimulator (ETS) for use during a Spinal Cord Stimulation (SCS) trial before implanting the permanent device.
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market
| Report Attributes | Details |
|---|---|
| Market Value in 2023 | US$ 103.7 million |
| Market Value in 2033 | US$ 129.2 million |
| Growth Rate | CAGR of 2.2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market may expand at a 2.2% CAGR from 2023 to 2033.
The market in 2022 recorded US$ 101.9 million.
China will exhibit a 2.5% CAGR throughout 2033.
AbbVie, ACTAVIS and Sandoz are the key players in this market.
From 2018 to 2022, the market rose at a 1.4% CAGR.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
5.3.1. Physical Therapy
5.3.2. Therapy via Drugs
5.3.2.1. Analgesics
5.3.2.2. Antidepressants
5.3.2.3. Corticosteroids
5.3.2.4. Others
5.3.3. Surgical Sympathectomy
5.3.4. Intrathecal Drug Pumps
5.3.5. Spinal Cord Stimulation
5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral Therapy
6.3.2. Intravenous Therapy
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Drug Stores
7.3.3. Retail Pharmacy
7.3.4. E-Commerce
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Therapy Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Therapy Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Therapy Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Therapy Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Therapy Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Therapy Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Therapy Type
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Therapy Type
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapy Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Therapy Type
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Therapy Type
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Therapy Type
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Therapy Type
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Therapy Type
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Therapy Type
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Therapy Type
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Therapy Type
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Therapy Type
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Therapy Type
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Therapy Type
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Therapy Type
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Therapy Type
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Therapy Type
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Therapy Type
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Therapy Type
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Therapy Type
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Therapy Type
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Therapy Type
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Therapy Type
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Therapy Type
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Therapy Type
16.22.2.2. By Route of Administration
16.22.2.3. By Distribution Channel
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Therapy Type
16.23.2.2. By Route of Administration
16.23.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Therapy Type
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Mallinckrodt Pharmaceuticals
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. GlaxoSmithKline plc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Mylan N.V.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Teva Pharmaceutical Industries Ltd.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. AbbVie
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. ACTAVIS
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Zydus Pharmaceuticals Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Sandoz
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Janssen Global Services LLC.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Medline Plus
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Complex Regional Pain Syndrome (CRPS) Market
